Company intelligence / Profile preview

Amrif Records

Wageningen, Gelderland, Netherlandsdesagri.gov.in ↗

Ownership: Private
Development stage: Other

Overview

Amrif is developing RESCAP, a recombinant alkaline phosphatase, as a natural and safe treatment for chronic inflammatory and age-related diseases. The company emphasizes the safety and tolerability of its approach but does not specify published clinical results or trial phases.

Therapeutic areas: OtherImmunology
Modalities: ProteinRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Amrif Records.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amrif Records.

Explore the full profile